Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

FHS
May 30, 2024
1:05 am

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and reduces body weight in type 2 diabetes patients after 24 weeks of treatment.

CDC endorses prophylactic antibiotics to reduce STIs in high-risk groups

The Centers for Disease Control and Prevention finalized its guidelines for post-exposure prophylaxis against bacterial sexually transmitted infections on Tuesday. For groups at higher risk

June 4, 2024

Pulse Oximetry Inaccuracies Delayed COVID-19 Treatment

Overestimation of oxygen saturation by pulse oximetry led to delayed delivery of COVID-19 therapy, and an unrecognized need for therapy among Black patients, according to

August 25, 2023

PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale | Psychedelic Invest

PsyBio Therapeutics Corp. (TSXV: PSYB / OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to

July 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.